Truffle’s recipe for company creation
Truffle Capital plans to deploy €250M fund to scour the U.S., Europe for IP to build biotechs, medtechs
Paris-based Truffle Capital has closed its €250 million ($277.9 million) BioMedTech fund to create new drug and medtech companies and nurture them through at least Phase II testing.
The fund will channel around 30% of its capital into drug development and 70% into medtech across 10 to 12 companies, mostly in France. Individual investments